Tauklarify Readers Agree Closely In Two Pivotal Studies
Five blinded readers cleared every accuracy bar across 617 tau PET scans. The specificity is elite, the sensitivity is softer, and no launch date exists yet.
The readers agree with each other. The open question is when any given clinic can order the scan.
Five independent readers met every prespecified accuracy target in two pivotal Tauklarify studies covering 617 tau PET scans, Lantheus reported Monday.
The evidence boundary comes first. Tauklarify, the florquinitau F 18 tracer also known as MK-6240, is cleared for adults who already have cognitive impairment and are being evaluated for Alzheimer's disease. It identifies tau neurofibrillary tangle pathology in that group. It isn't a general screen for worried people without symptoms, and its safety and effectiveness aren't established for tauopathies outside Alzheimer's.
In the first study, CE-20-01, with 279 scans, reader sensitivity ran from 79.9 to 88.5 percent and specificity from 97.9 to 99.3 percent. In the second, CE-23-01, with 338 scans, sensitivity ran from 68.2 to 82.4 percent and specificity from 93.5 to 99.4 percent. Agreement among readers was high in both, with Fleiss kappa values of 0.92 and 0.86. The success rule required at least the same three of five readers to clear a 60 percent lower confidence bound on both measures, and all five did.
Read in absolute terms, the tracer's strong side is ruling in. Majority-read positive predictive value reached 98.4 percent in the first study and 99.3 percent in the second, so a positive read is rarely wrong. The soft side is ruling out. Majority-read negative predictive value was 89.0 percent in the first study and 82.3 percent in the second, so a negative scan doesn't close the file on a symptomatic patient.
The safety pool covered 1,734 participants from the U.S. POINTER and AIBL cohorts who received at least one dose. Lantheus says the tracer was generally well tolerated, with headache the most commonly reported event. The results were presented Monday at the CTAD 2026 meeting in Boston.
The University of Wisconsin supplied a large share of the underlying evidence. UW researchers were among the tracer's earliest adopters, ran more than 2,200 scans across 800 to 900 volunteers, and held National Institutes of Health funding for the work from 2017. UW Health is now building a clinical tau PET program inside its geriatric memory clinics, with trained scan readers and dedicated imaging capacity.
What doesn't exist yet is a launch date. Lantheus hasn't announced a commercial timeline, and UW says it's preparing so its clinics can move when supply arrives. The approval landed in August. The data behind it is public now. The scan itself is still on its way to patients.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.